Mechanistically, TMAO disrupts insulin signaling by activating inflammatory pathways, such as the NLRP3 inflammasome, which impairs insulin receptor substrate-1 (IRS-1)-mediated signaling, leading to insulin resistance and glucose intolerance [19]. The gene discussed is IRS1; the disease is Glucose intolerance.